INTERNATIONAL JOURNAL OF CARDIOVASCULAR RESEARCH & INNOVATION
Oct-Dec 2024, VOL. 2, ISSUE 4, pp. 9-12
https://doi.org/10.61577/ijcri.2024.1000020

RESEAPRO JOURNALS

MINI REVIEW

OPEN ACCESS

Impact of intensive diuretic therapy on secondary mitral regurgitation progression in ADHF patients

Sasmita Das

Department of Chemistry, Utkal University, Odisha, India

ABSTRACT

Acute decompensated heart failure (ADHF) remains a frequent occurrence with dangerous consequences in which the heart failure patient reports a dramatic increase in the severity of their problems, this imposes a high burden of disease with healthcare costs. ADHF's epidemiology demonstrates a frequent percentage of emergency admissions, a fair share of the subjects available are acute care patients. Its pathophysiology encompasses multifactorial states of fluid overload, decreased cardiac output, and neurohormonal stimulation. Among ADHF's common complications is secondary mitral regurgitation (SMR). SMR is when the blood flows back to the left atrium because the valve fails to close properly, this often accompanies ventricular enlargement and alteration of heart structure. This can exacerbate the patient's heart failure and worsen the outlook for further events. Patients with ADHF are managed with diuretic therapy where the focus is on the improvement of congestion and the quality of life of patients. In this regard, it classifies them into two types, normal diuresis and pathological diuresis. Intensive diuretic therapy includes greater doses or continuous infusions that are utilized to reduce the fluid volume quickly, and this can alter the rate of SMR increase. The goal of this review is not only to review the available literature on the effectiveness of diuretic therapy in treating fluid in the form of edema but also to address the complications geared toward the ADHF to inform clinical practice and improve patient outcomes.

KEYWORDS

Acute decompensated heart failure (ADHF); Secondary mitral regurgitation (SMR); Diuretic therapy; Fluid overload; Intensive diuretic strategies; Prognosis

ARTICLE HISTORY

Received 09 October 2024; Revised 06 November 2024; Accepted 13 November 2024

Introduction

Acute decompensated heart failure (ADHF) is a prevalent and serious condition characterized by the abrupt worsening of heart failure symptoms, leading to significant morbidity and healthcare burden. The epidemiology of ADHF reveals high hospitalization rates, with a substantial proportion of patients requiring acute care. The pathophysiology of ADHF involves a complex interplay of factors, including fluid overload, reduced cardiac output, and neurohormonal activation [1].

Secondary mitral regurgitation (SMR) is a frequent complication in patients with ADHF, defined by the backflow of blood into the left atrium due to compromised valve function. SMR is often secondary to left ventricular dilation and altered geometry, which can exacerbate heart failure symptoms and worsen overall prognosis [2].

Diuretic therapy serves as a cornerstone in the management of ADHF, primarily aimed at alleviating congestion and improving patients' quality of life. This review will differentiate between standard and intensive diuretic strategies, with a particular emphasis on the latter. Intensive diuretic therapy involves higher doses or continuous infusions to achieve rapid fluid removal, which may have significant implications for the progression of SMR. Although intensive diuresis can quickly alleviate symptoms, it also raises the chances of negative consequences like electrolyte imbalances, kidney damage, and potentially worsening long-term survival rates. It is important to find a balance between the advantages of quick relief from congestion and the risks involved. Ongoing studies are working on improving dosage methods to reduce harm and improve patient outcomes.

Mechanisms of SMR in ADHF

The mechanisms underlying secondary mitral regurgitation (SMR) in patients with acute decompensated heart failure (ADHF) are multifaceted. Cardiac remodeling is a key element, in which enlargement of the left ventricle (LV) causes changes in structure that negatively impact the function of the mitral valve, leading to regurgitation [3,4].

Additionally, papillary muscle dysfunction plays a critical role. This malfunction, frequently caused by reduced blood supply or excessive fluid volume, hinders the regular functioning of the mitral valve system, resulting in higher regurgitation flow. The imbalance between the left ventricle and the mitral valve can greatly increase the seriousness of SMR [5].

Changes in the shape of the heart also play a role in SMR. Changes in the left ventricle shape interfere with the mitral valve closure, resulting in increased severity of regurgitation. These alterations form a harmful loop, where deteriorating heart failure worsens SMR, thus leading to an additional decline in heart function.

Understanding these mechanisms is crucial for developing targeted therapeutic strategies aimed at mitigating the progression of SMR in ADHF patients (Figure 1).

***Correspondence:** Ms. Sasmita Das, Department of Chemistry, Utkal University, Odisha, India. e-mail: sasmitadas542@gmail.com



Figure 1. The progression of Secondary Mitral Regurgitation (SMR) in the context of Acute Decompensated Heart Failure (ADHF).

Diuretic Therapy: Pharmacological Overview

Loop diuretics, like furosemide, are commonly used in the treatment of acute decompensated heart failure (ADHF) because of their effectiveness. Thiazide diuretics could be used as additional treatment in specific situations, especially for patients who do not respond well to loop diuretics.

Loop diuretics work by blocking the reabsorption of sodium and chloride in the ascending limb of the loop of Henle, resulting in higher urine production. This decrease in intravascular volume helps relieve congestion, leading to better clinical symptoms like shortness of breath and swelling in the extremities [6,7].

The main goal of diuretic treatment is to quickly remove fluid to lower preload and lower the chance of pulmonary congestion. Nevertheless, a cautious approach is necessary when administering diuretics to prevent possible complications such as kidney damage and imbalances in electrolytes [8-10].

Continual patient monitoring is crucial for maximizing the benefits of diuretic treatment and balancing symptom relief with potential side effects. Further research is needed to improve treatment strategies as the use of diuretics in managing ADHF evolves [11].

Intensive Diuretic Therapy: Clinical Evidence

Intensive diuretic therapy is characterized by the administration of higher doses or continuous infusions of diuretics to achieve aggressive fluid removal in patients with acute decompensated heart failure (ADHF). This approach contrasts with standard diuretic protocols, which typically utilize lower doses [8].

Several clinical studies have investigated the efficacy of intensive diuretic therapy. An example is the trial of Diuretic Optimization Strategies Evaluation (DOSE), which showed that using high doses of diuretics results in quicker removal of fluids compared to regular dosing. This leads to better symptoms and hemodynamic parameters. Patients undergoing intense diuretic treatment tend to experience faster symptom relief and shorter hospital stays, according to these results [12].

The emerging evidence indicates that intensive diuretic therapy may influence the progression of secondary mitral regurgitation (SMR). Research examining how aggressive fluid removal impacts changes in mitral regurgitation severity has revealed that prompt intervention can help avoid the exacerbation of SMR in patients with ADHF. For instance, a recent study showed that patients who had a major decrease in fluid levels through intense diuretic treatment saw a decrease in the severity of SMR while in the hospital.

However, it is important to analyze these results considering the possible dangers of aggressive diuretic treatment, such as imbalances in electrolytes and declining renal function. Continuous investigation is essential to clarify the lasting impacts of aggressive diuretic treatment on heart failure symptoms and patient outcomes, specifically in terms of SMR advancement.

Risks and Complications of Intensive Diuretic Therapy

Although intensive diuretic treatment is successful in controlling acute decompensated heart failure (ADHF), it does come with certain risks. A major issue is the occurrence of electrolyte imbalances, such as hypokalemia, hypomagnesemia, and hyponatremia. These disparities may result in severe complications such as irregular heartbeats, decreased muscle strength, and higher mortality rates [13].

Another critical risk associated with aggressive diuresis is the potential for acute kidney injury (AKI). The use of high doses of diuretics can adversely affect renal function, necessitating close monitoring of kidney parameters throughout treatment. If renal impairment occurs, it may complicate the management of ADHF and impede fluid management strategies.

Excessive fluid removal can inadvertently worsen heart failure symptoms, particularly if dehydration occurs. Clinicians need to find a careful equilibrium between effectively removing fluids and ensuring a sufficient volume status to prevent unwanted consequences [14].

Due to these possible issues, it is essential to closely monitor patients while undergoing intensive diuretic treatment. Frequent evaluation of hydration status, electrolyte levels, and kidney function allows for prompt modifications to treatment strategies, maintaining patient safety and maximizing therapeutic effectiveness.

Strategies for Optimizing Diuretic Therapy

Enhancing diuretic treatment in patients experiencing acute decompensated heart failure (ADHF) necessitates employing a variety of strategies. Initially, selecting the right patients is very important. Clinicians need to determine which patients would benefit from aggressive diuretic treatment by considering clinical factors such as the extent of fluid buildup and initial kidney function.

Regular surveillance is crucial when undergoing diuretic therapy. Clinicians must regularly evaluate fluid status,

https://doi.org/10.61577/ijcri.2024.1000020

electrolyte levels, and renal function to inform treatment decisions. This alertness enables timely changes in diuretic dosage to reduce complications and enhance symptom control. A multidisciplinary approach is also vital in managing ADHF. Collaboration among healthcare professionals, including cardiologists, nephrologists, and dietitians, ensures comprehensive care. Each discipline can contribute valuable insights into fluid management, dietary recommendations, and the overall treatment plan, enhancing patient outcomes [15].

Furthermore, educating individuals on the significance of following prescribed diuretic regimens is important. Patients must be notified of potential adverse reactions and the importance of keeping scheduled follow-up appointments. This comprehensive strategy creates a nurturing atmosphere for patients, promoting their active involvement in their treatment. Healthcare providers can improve clinical outcomes and reduce risks by utilizing these strategies to optimize diuretic therapy for patients with ADHF.

Future Directions and Research Gaps

The changing diuretic management in acute decompensated heart failure (ADHF) presents chances for creative solutions. New treatments like vasopressin antagonists and innovative medications targeted at the kidneys show potential for improving fluid control methods. Studying these agents may offer an understanding of their possible roles in addition to regular diuretic treatment.

Exploration of vasopressin antagonists

While these are suggested as potential aids in fluid management, further studies are needed to assess their specific mechanisms, efficacy, and safety in ADHF settings. Clinical trials could focus on how vasopressin antagonists impact patients differently from standard diuretics, particularly regarding secondary mitral regurgitation (SMR) progression and renal outcomes.

Kidney-targeted therapies

Kidney function is vital in ADHF treatment, and new medications aimed at enhancing renal fluid management may improve outcomes. Investigations could focus on how these kidney-specific therapies interact with conventional diuretics, aiming to establish protocols that improve fluid clearance without risking renal impairment or electrolyte imbalances.

Long-Term Impact of aggressive diuresis on SMR and cardiac function

The document suggests immediate benefits, but more research is required to determine if these effects persist. Longitudinal studies could provide insight into the effects of aggressive diuresis on SMR progression, cardiac remodeling, and mortality over time, helping refine treatment strategies to maximize long-term patient outcomes.

Personalized diuretic protocols

As patient variability in kidney function and comorbid conditions influences treatment response, studies focusing on individualized diuretic dosing protocols are essential. These would consider patient-specific factors like baseline renal function, fluid status, and comorbid conditions. Research could aim to develop predictive models or biomarkers that tailor diuretic regimens to optimize effectiveness while minimizing risks.

It is imperative to identify shortcomings in existing research as well. Additional research is required to investigate the lasting impact of aggressive diuretic treatment on secondary mitral valve leakage and overall cardiac performance. Although there are indications of immediate advantages, the lasting effects on life expectancy and overall well-being are still not known.

Further studies are needed to create personalized diuretic plans that take into account specific patient factors like initial kidney function, other health conditions, and how they respond to treatment. Tailored methods can improve treatment effectiveness and reduce potential harm.

Promoting continued studies in this area will be crucial for progressing our knowledge of diuretic treatment in ADHF, ultimately resulting in better patient results and improved care quality [16,17].

Conclusions

This review emphasizes the important influence of aggressive diuretic treatment on the development of secondary mitral regurgitation (SMR) in individuals affected by acute decompensated heart failure (ADHF). Aggressive use of diuretics can result in fast relief of symptoms and better heart function, but there are risks involved such as changes in electrolytes and kidney damage. In treating ADHF, it is crucial to take a personalized, patient-focused strategy that takes into account unique risk factors and the necessity for continuous observation. The combined work of a diverse team can improve treatment effectiveness and guarantee thorough care. It is stressed that there is a requirement for ongoing studies, specifically focused on the lasting effects of intense diuretic treatment and how it impacts the progression of SMR. Progress in this field will ultimately help in maximizing treatment plans, enhancing overall quality of care, and improving patient outcomes for those with ADHF.

Disclosure Statement

No potential conflict of interest was reported by the author.

References

1. Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021;128(10): 1468-1486. https://doi.org/10.1161/CIRCRESAHA.121.318186
2. Kurniawan DA, Prasetya I, Widito S, Martini H. Acute Decompensated Heart Failure: Current Role of Diuretics and Ultrafiltration. Heart Sci J. 2023;4(1):5-15. https://doi.org/10.21776/ub.hsj.2023.004.01.2
3. O'Gara PT, Mack MJ. Secondary mitral regurgitation. N Engl J Med. 2020;383(15):1458-1467. https://doi.org/10.1056/NEJMcp1903331
4. Huang AL, Dal-Bianco JP, Levine RA, Hung JW. Secondary mitral regurgitation: Cardiac remodeling, diagnosis, and management. Struct Heart. 2023;7(3):100129. https://doi.org/10.1016/j.shj.2022.100129
5. Lancellotti P, Zamorano JL, Vannan MA. Imaging challenges in secondary mitral regurgitation: unsolved issues and perspectives. Circ Cardiovasc Imaging. 2014;7(4):735-746. https://doi.org/10.1161/CIRCIMAGING.114.000992
6. Wilson BJ, Bates D. Diuretic Strategies in Acute Decompensated

https://doi.org/10.61577/ijcri.2024.1000020

Heart Failure: A Narrative Review. Can J Hosp Pharm. 2024;77(1). https://doi.org/10.4212/cjhp.3323
7. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. https://doi.org/10.1056/NEJMoa1005419
8. Ronco C, Kellum JA. Use of diuretics in heart failure: a precarious balance. Am J Kidney Dis. 2011;58(3):340-342. https://doi.org/10.1053/j.ajkd.2011.06.005
9. Kennelly P, Sapkota R, Azhar M, Cheema FH, Conway C, Hameed A. Diuretic therapy in congestive heart failure. Acta Cardiol. 2022; 77(2):97-104. https://doi.org/10.1080/00015385.2021.1878423
10. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24): 2145-2153. https://doi.org/10.1016/j.jacc.2011.10.910
11. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-155. https://doi.org/10.1002/ejhf.1369
12. Simonis G, Ebner B, Katzke S, Strasser RH. Diuretics in acute heart failure – sensible therapy or necessary evil? Cardiol Up2date. 2012;8(2):109-113. https://doi.org/10.1055/s-0032-1309764
13. Aspromonte N, Cruz DN, Valle R, Bonello M, Tubaro M, Gambaro G, et al. Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opin Drug Metab Toxicol. 2011;7(9):1049-1063. https://doi.org/10.1517/17425255.2011.586629
14. Freda BJ, Slawsky M, Mallidi J, Braden GL. Decongestive treatment of acute decompensated heart failure: cardiorenal implications of ultrafiltration and diuretics. Am J Kidney Dis. 2011;58(6): 1005-1017. https://doi.org/10.1053/j.ajkd.2011.07.023
15. Nwosu C, Mezue K, Bhagatwala K, Ezema N. A practical comprehensive approach to management of acute decompensated heart failure. Curr Cardiol Rev. 2016;12(4):311-317. https://doi.org/10.2174/1573403x12666160301120030
16. De Maria R. Efficient, Efficacious, Effective: Still a Long Way to Go for Diuretic Treatment of Acute Decompensated Heart Failure. J Card Fail. 2018;24(7):439-441. https://doi.org/10.1016/j.cardfail.2018.06.002
17. Givertz MM, Teerlink JR, Albert NM, Canary CA, Collins SP, Colvin-Adams M, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail. 2013;19(6):371-389. https://doi.org/10.1016/j.cardfail.2013.04.002

https://doi.org/10.61577/ijcri.2024.1000020